ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-72062-y
Affiliations:
8
Authors:
14
Go to article
Institutions Authors Share
Zhongshan Hospital, Fudan University, China
7.000000
 0.50
Fudan University, China
3.000000
 0.21
Shanghai East Hospital, Tongji University, China
2.000000
 0.14
Shandong Provincial Hospital, China
1.000000
 0.07
Shanghai General Hospital, SJTU, China
1.000000
 0.07
Interested in Oncology and Carcinogenesis?